The diagnosis and prognosis of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease are still a major societal challenge. Much can be learned from the structural and functional changes in the brain that can be studied using neuroimaging modalities such as Positron Emission Tomography, Electroencephalography and Magnetic Resonance. Multi-centre studies give the opportunity to accumulate large amounts of data that might allow for more reliable measurements. However, is this really the case? Harmonization of image acquisition and data analysis remains challenging since biomarkers should be specific to the disease. As a result, an inadequate level of calibration protocols prevents comparisons of data from different studies and delays the use of biomarkers in clinical research and drug discovery, ultimately leading to uneven and suboptimal quality of care and the slowing of drug discovery.

This project aims to identify barriers to the large-scale harmonization of imaging biomarkers in neurodegenerative diseases. This goal will first be addressed by conducting a detailed questionnaire in expert centres to detect the main problems associated with the level of calibration protocols. Second, from the information gathered we will develop guidelines to address the most critical barriers for neuroimaging harmonization. The guidelines will help funding agencies to identify topics and actions for funding, with the ultimate aim of developing best practices to be followed for the elaboration of biomarkers in neurodegenerative diseases.

Coordinator: Giovanni B. Frisoni

E: Giovanni.Frisoni@hcuge.ch
T: +41 223055760
W: http://www.sra-ned.org/sra-ned/

Working Group Members:

Wilhelmus H. Drinkenburg, Janssen R&D / J&J Pharmaceutical Companies, Belgium
Jakub Hort, Charles University, Czech Republic
Zuzana Nedelska, St. Anne’s University Hospital, Czech Republic
Marie Chupin, CNRS / ICM Institut du Cerveau et de la Moelle épinière, France
Marie-Odile Habert, University Pierre & Marie Curie, France
Jean-François Mangin, Neurospin, France
Pierre Payoux, University of Toulouse, France
Alexander Drzezga, University Hospital of Cologne, Germany
Christoph H. T. Mulert, University Medical Center Hamburg-Eppendorf, Germany
Stefan Teipel, University of Rostock / DZNE, Germany
Claudio Babiloni, University of Rome "La Sapienza", Italy
Flavio Nobili, University of Genoa / IRCCS AOU San Martino-IST, Italy
Jorge Jovicich, University of Trento, Italy
Frederik Barkhof, VU University Medical Center Amsterdam, Netherlands
Bart van Berckel, VU University Medical Center Amsterdam, Netherlands
Tormod Fladby, Akershus University Hospital / University of Oslo, Norway
Dag Årsland, Stavanger University Hospital, Norway
Rok Berlot, University Medical Centre Ljubljana, Slovenia
Vesna Jelic, Karolinska University Hospital, Sweden
Agneta Nordberg, Karolinska Institutet, Sweden
Eric Westman, Karolinska Institutet, Sweden
Giovanni B. Frisoni, University of Geneva, Switzerland
Valentina Garibotto, Hôpitaux Universitaires de Gèneve, Switzerland
Micah M. Murray, University of Lausanne, Switzerland
Derya Durusu Emek-Savas, Dokuz Eylul University, Turkey
Görsev G. Yener, Dokuz Eylul University, Turkey
Karl Herholz, University of Manchester, UK
Clare E. Mackay, University of Oxford, UK
Rachael I. Scahill, University College London, UK
David L. Thomas, UCL Institute of Neurology, UK
Advisory Group
Chris Rowe, University of Melbourne, Australia
Hiroshi Matsuda, National Center of Neurology and Psychiatry, Tokyo, Japan
Sieske Sikkes, VU University Medical Center Amsterdam, the Netherlands
Jean François Démonet, Centre Hospitalier Universitaire Vaudois University Hospital, Lausanne, Switzerland
Clifford R. Jack, Mayo Clinic, Rochester, USA
William B. Jagust, University of California Berkeley, USA
Leslie Prichep, New York School of Medicine, USA